Physician profile
Stuart L Solomon
NPI 1336148568
$7,195.87
in general payments reported to CMS, 2019-2025
28 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $877 · 2021: $969 · 2022: $1,049 · 2023: $1,431 · 2024: $1,198 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,909.49 | 2019-2025 | Cardiomems, Confirm Rx, Gallant |
| Medtronic, INC. | $677.94 | 2021-2025 | Azure Xt Dr Mri Surescan, Hawkone, Mycarelink |
| Biotronik INC. | $521.35 | 2019-2021 | |
| Medtronic Vascular, INC. | $397.13 | 2019-2020 | |
| Boston Scientific Corporation | $327.50 | 2020-2025 | Watchman Flx, Accolade Sr, General - Therapies |
| Pfizer INC. | $302.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $278.51 | 2020-2025 | Eliquis, Camzyos |
| Amgen INC. | $269.46 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $231.64 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $169.24 | 2021-2024 | Lokelma, Farxiga |
| Acutus Medical, INC. | $134.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $112.06 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $101.92 | 2022-2024 | Evkeeza, Praluent |
| Heartflow, INC. | $100.49 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $95.90 | 2022-2023 | Optimizer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $85.00 | 2019 | |
| G Medical Diagnostic Services, INC. | $65.88 | 2019 | |
| Alnylam Pharmaceuticals INC. | $60.55 | 2023-2025 | Amvuttra, Onpattro |
| Tactile Systems Technology INC | $60.04 | 2024 | Entre Plus, Flexitouch Plus |
| Biosense Webster, INC. | $50.44 | 2023 | Carto 3 |
| Sanofi-Aventis U.S. LLC | $50.37 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $44.43 | 2024-2025 | Verquvo |
| Esperion Therapeutics, INC. | $33.85 | 2024-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $32.16 | 2024 | |
| Cardiva Medical, INC. | $25.85 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.02 | 2022 | |
| Glaxosmithkline, LLC. | $17.88 | 2025 | Shingrix, Arexvy |
| Irhythm Technologies, INC. | $16.63 | 2024 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.